Femasys INC 8-K filings

Femasys Inc. announced the successful pricing of a $3.06 million underwritten public offering and a concurrent $1.44 million private placement, totaling $4.5 million in gross proceeds, alongside a new $10 million equity line of credit to fund its strategic initiatives.

Femasys Inc. has received a notice from The Nasdaq Stock Market LLC indicating non-compliance with continued listing requirements due to its market value of listed securities falling below the $35.0 million minimum, alongside failing alternative financial standards.

Femasys reports a 25.9% increase in sales driven by FemaSeed, alongside key regulatory approvals and partnerships, but also a widening net loss and concerns about near-term cash runway.

Femasys reports increased sales and R&D expenses for 2024, alongside European approval for its FemBloc permanent birth control system and strategic partnerships.

Femasys Inc. announces strategic distribution partnerships with Comercial Medico Quirurigca, SA and Durgalab to commercialize FemBloc in Spain, marking its first EU distribution agreements.

Femasys Inc. announces European regulatory approval for its FemBloc delivery system, marking a significant advancement in non-surgical permanent birth control for women.

Femasys Inc. announced a significant 127% increase in sales for the third quarter of 2024, driven by the commercialization of FemaSeed and FemVue, alongside strategic partnerships and regulatory approvals.

Femasys Inc. announced a significant 127% increase in sales for the third quarter of 2024, driven by the commercialization of its FemaSeed and FemVue products, alongside strategic partnerships and regulatory approvals.

Femasys Inc. released an updated investor presentation detailing their progress in developing innovative solutions for women's reproductive health, including infertility treatments and permanent birth control.

Femasys has partnered with two distributors in Spain to commercialize its FemaSeed product, with a minimum purchase commitment of $1.3 million over the next year.

Femasys Inc. has announced it received FDA 510(k) clearance to market FemChec, an innovative diagnostic solution for fallopian tube checks.

Femasys Inc. released an updated investor presentation detailing their progress in developing and commercializing innovative products for women's reproductive health, including infertility treatments and permanent birth control.

Femasys Inc. has announced the receipt of CE Mark certification and Canadian approval for its FemVue MINI, a compact and eco-friendly fallopian tube assessment solution.

Femasys reported its Q2 2024 financial results, highlighted by CE Mark approval for four women's health products and the completion of its commercial team build-out.

Femasys Inc. held its annual meeting on July 12, 2024, where stockholders elected a director and ratified the appointment of KPMG LLP as the independent accounting firm.

Femasys has received CE Mark approval for four of its women's health products, enabling the company to begin commercialization efforts in Europe.

Femasys reported its Q1 2024 financial results, highlighting progress in its infertility portfolio and the FemBloc pivotal trial, while also noting increased R&D expenses and a net loss.

Femasys Inc. released an updated corporate presentation detailing their progress in developing and commercializing innovative products for women's reproductive health, including infertility treatments and permanent birth control.

Femasys reported its 2023 financial results, highlighted by FDA clearance of FemaSeed and secured funding expected to last into the second half of 2025.

Femasys reports a 24% pregnancy rate in women with severe male factor infertility using FemaSeed, more than double the rate of traditional IUI.

Femasys has completed its first in-office commercial procedure using the FDA-cleared FemaSeed infertility solution, marking a significant step towards broader availability.

Femasys has received FDA clearance for its FemaSeed intratubal insemination product, offering a less costly and less risky alternative to IVF for infertility treatment.

Femasys Inc. has appointed Richard Spector as its Chief Commercial Officer to lead the commercial launch of FemaSeed and other products.